Taken together, the CRY stabilizer, TH301, demonstrates a superior efficacy in reducing human pancreatic cancer cell viability and growth, compared to other CRY modulators tested herein (KL001 and KS15). This evidence concerns the gene CRYL1 and pancreatic neoplasm.